title: Skp2 is a promising therapeutic target in breast cancer.
abstract: Breast cancer is the most common type of cancer among American women, and remains the second leading cause of cancer-related death for female in the United States. It has been known that several signaling pathways and various factors play critical roles in the development and progression of breast cancer, such as estrogen receptor, Notch, PTEN, human epidermal growth factor receptor 2, PI3K/Akt, BRCA1, and BRCA2. Emerging evidence has shown that the F-box protein S-phase kinase associated protein 2 (Skp2) also plays an important role in the pathogenesis of breast cancer. Therefore, in this brief review, we summarize the novel functions of Skp2 in the pathogenesis of breast cancer. Moreover, we provide further evidence regarding the state of our knowledge toward the development of novel Skp2 inhibitors especially natural "chemopreventive agents" as targeted approach for the prevention and/or treatment of breast cancer.
authors.affiliation: Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
authors.forename: Zhiwei
authors.initials: Z
authors.lastname: Wang
authors.forename: Hidefumi
authors.initials: H
authors.lastname: Fukushima
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Inuzuka
authors.forename: Lixin
authors.initials: L
authors.lastname: Wan
authors.forename: Pengda
authors.initials: P
authors.lastname: Liu
authors.forename: Daming
authors.initials: D
authors.lastname: Gao
authors.forename: Fazlul H
authors.initials: FH
authors.lastname: Sarkar
authors.forename: Wenyi
authors.initials: W
authors.lastname: Wei